Quest Diagnostics Incorporated (BIT:1QDX)
Italy · Delayed Price · Currency is EUR | Market Cap | 22.09B +36.0% |
| Revenue (ttm) | 10.12B +9.9% |
| Net Income | 926.07M +11.8% |
| EPS | 8.24 +12.8% |
| Shares Out | n/a |
| PE Ratio | 23.85 |
| Forward PE | 19.66 |
| Dividend | 1.49 (0.72%) |
| Ex-Dividend Date | Jul 7, 2026 |
| Volume | n/a |
| Open | 206.90 |
| Previous Close | 206.90 |
| Day's Range | 206.90 - 206.90 |
| 52-Week Range | 138.70 - 206.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceu... [Read more]
Financial Performance
In 2025, Quest Diagnostics's revenue was $11.04 billion, an increase of 11.78% compared to the previous year's $9.87 billion. Earnings were $988.00 million, an increase of 14.09%.
Financial numbers in USD Financial StatementsNews
Quest Diagnostics price target raised to $265 from $245 at BofA
BofA raised the firm’s price target on Quest Diagnostics (DGX) to $265 from $245 and keeps a Buy rating on the shares after the company reported “solid” Q2 results and…
Quest Diagnostics price target raised to $232 from $220 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Quest Diagnostics (DGX) to $232 from $220 and keeps a Neutral rating on the shares. Quest Diagnostics’ Q2 results featured…
Quest Diagnostics price target raised to $260 from $235 at Mizuho
Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $260 from $235 and keeps an Outperform rating on the shares. The firm cites the company’s strong organic growth…
Quest Diagnostics price target raised to $255 from $236 at Baird
Baird raised the firm’s price target on Quest Diagnostics (DGX) to $255 from $236 and keeps a Neutral rating on the shares. The firm updated its model followng solid Q2…
Quest Diagnostics price target raised to $250 from $230 at Barclays
Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $250 from $230 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Quest Diagnostics price target raised to $245 from $225 at Jefferies
Jefferies raised the firm’s price target on Quest Diagnostics (DGX) to $245 from $225 and keeps a Buy rating on the shares. Revenue of $3.04B beat by 2%, while EPS…
Quest Diagnostics Earnings Call Transcript: Q2 2026
Q2 2026 saw over 10% revenue growth and a 19% rise in adjusted EPS, driven by strong demand across all channels and operational improvements. Full-year guidance was raised, with robust performance in advanced diagnostics and stable financial metrics.
Quest Diagnostics Earnings release: Q2 2026
Quest Diagnostics released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Quest Diagnostics Slides: Q2 2026
Quest Diagnostics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Quest Diagnostics Quarterly report: Q2 2026
Quest Diagnostics has published its Q2 2026 quarterly earnings report on July 23, 2026.
Quest Diagnostics raises annual forecast on testing demand
Quest Diagnostics on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped the company beat second-quarter estimates.
Quest Diagnostics reports Q2 adjusted EPS $3.12, consensus $2.82
Reports Q2 revenue $3.04B, consensus $2.97B. “Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative ...
Quest Diagnostics ups FY26 adjusted EPS view to $11.05-$11.25 from $10.63-$10.83
Consensus $10.77. Raises FY26 revenue view to $11.95B-$12.05B from $11.78B-$11.9B, consensus $11.85B. Backs FY26 capital expenditures view $550M.
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted di...
HCA preannouncement negative for Quest, Labcorp, says Barclays
Barclays views HCA Healthcare’s (HCA) preannouncement on Affordable Care Act coverage lost during Q2 is a negative read-through for Quest Diagnostics (DGX) and Labcorp (LH). HCA’s Affordable Care Act ...
Quest Diagnostics price target raised to $236 from $232 at Baird
Baird raised the firm’s price target on Quest Diagnostics (DGX) to $236 from $232 and keeps a Neutral rating on the shares. The firm updated its model to include thouths…
Quest Diagnostics integrates Haystack MRD ctDNA test within OncoEMR
Quest Diagnostics (DGX) announced it is integrating its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR, an electronic health record from Fl...
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD SECAUCUS, N.J., July 8, 2026 /PRNewswire/ -- Quest ...
Quest Diagnostics’ Haystack MRD test receives New York SDOH approval
Quest Diagnostics (DGX) announced that the New York State Department of Health’s, or NYSDOH, Clinical Laboratory Evaluation Program, or CLEP, has approved the company’s Haystack MRD test, a circulatin...
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 /P...
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
Published in Nature Communications, the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to the thr...
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
SECAUCUS, N.J., June 17, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 finan...
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
SECAUCUS, N.J., June 16, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
Quest Diagnostics management to meet with Oppenheimer
Meeting to be held in New Jersey on June 8 hosted by Oppenheimer.
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., May 19, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend ...